BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alnylam Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Alnylam Pharmaceuticals's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07102628-1034@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT07102628)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Evaluation of Efficacy and Safety of Early in Hospital In
 itiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
 \nEstimated primary completion: 16 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07102628
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05662319-10760@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Qfitlia (Fitusiran): Phase 3 readout est. (NCT05662319)
DESCRIPTION:Qfitlia (Fitusiran)\, phase 3.\nStudy: A Study to Test a Medici
 ne (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in
  Male Adolescent or Adult Participants With Severe Hemophilia\nEstimated p
 rimary completion: 25 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/fitusiran#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05662319
URL:https://assetmemo.bio/drug/fitusiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030428-1034@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05030428)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study of Inclisiran to Prevent Cardiovascular (CV) Events
  in Participants With Established Cardiovascular Disease\nEstimated primar
 y completion: 10 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05030428
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393712-697@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Mivelsiran: Phase 2 readout est. (NCT06393712)
DESCRIPTION:Mivelsiran\, phase 2.\nStudy: A Phase 2 Trial of ALN-APP in Pat
 ients With Cerebral Amyloid Angiopathy\nEstimated primary completion: 9 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mivelsiran
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 93712
URL:https://assetmemo.bio/drug/mivelsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05648214-6782@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:ALN-PNP: Phase 1/2 readout est. (NCT05648214)
DESCRIPTION:ALN-PNP\, phase 1/2\, MASH / NASH.\nStudy: A Trial to Learn if 
 ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participant
 s With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)\nE
 stimated primary completion: 10 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/aln-pnp#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05648214
URL:https://assetmemo.bio/drug/aln-pnp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06836609-6930@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:ALN-CIDEB: Phase 1/2 readout est. (NCT06836609)
DESCRIPTION:ALN-CIDEB\, phase 1/2\, MASH / NASH.\nStudy: A Study to Evaluat
 e ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated St
 eatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepat
 itis (MASLD/MASH)\nEstimated primary completion: 17 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06836609
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223203-10761@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Nucresiran: Phase 3 readout est. (NCT07223203)
DESCRIPTION:Nucresiran\, phase 3\, Transthyretin Amyloidosis with Polyneuro
 pathy.\nStudy: TRITON-PN: A Study to Evaluate the Efficacy and Safety of N
 ucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyn
 europathy\nEstimated primary completion: 27 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nucresiran#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07223203
URL:https://assetmemo.bio/drug/nucresiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813911-1034@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06813911)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Backgrou
 nd Inclisiran in Participants With Elevated Lp(a) and Established ASCVD\nE
 stimated primary completion: 3 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06813911
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597006-1034@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597006)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Safety\, Tolerability and Efficacy of I
 nclisiran in Children With Homozygous Familial Hypercholesterolemia\nEstim
 ated primary completion: 21 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06597006
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597019-1034@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597019)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Efficacy and Safety of Inclisiran in Ch
 ildren With Heterozygous Familial Hypercholesterolemia\nEstimated primary 
 completion: 21 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06597019
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679946-10756@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:AMVUTTRA (Vutrisiran): Phase 3 readout est. (NCT06679946)
DESCRIPTION:AMVUTTRA (Vutrisiran)\, phase 3\, Transthyretin Amyloidosis wit
 h Cardiomyopathy.\nStudy: A Study to Evaluate Vutrisiran in Patients With 
 Transthyretin Amyloidosis With Cardiomyopathy\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vut
 risiran#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06679946
URL:https://assetmemo.bio/drug/vutrisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519475-6912@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Rapirosiran (ALN-HSD): Phase 2 readout est. (NCT05519475)
DESCRIPTION:Rapirosiran (ALN-HSD)\, phase 2\, MASH / NASH.\nStudy: A Precis
 ion Medicine Approach Using Gene Silencing to Treat a Chronic Liver Diseas
 e Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult 
 Participants at Increased Genetic Risk for This Condition\nEstimated prima
 ry completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rapirosiran-aln-hsd#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05519475
URL:https://assetmemo.bio/drug/rapirosiran-aln-hsd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541704-5168@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cemdisiran: Phase 3 readout est. (NCT06541704)
DESCRIPTION:Cemdisiran\, phase 3\, Age-Related Macular Degeneration.\nStudy
 : A Study Investigating Subcutaneously Administered Pozelimab in Combinati
 on With Cemdisiran or Cemdisiran Alone in Adult Participants With Geograph
 ic Atrophy\nEstimated primary completion: 31 July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cemdisiran#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06541704
URL:https://assetmemo.bio/drug/cemdisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05744921-5168@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20281010
DTEND;VALUE=DATE:20281011
SUMMARY:Cemdisiran: Phase 3 readout est. (NCT05744921)
DESCRIPTION:Cemdisiran\, phase 3.\nStudy: A Study in Adult Patients With Pa
 roxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Tre
 atment With Pozelimab + Cemdisiran Combination Therapy is and How Well it 
 Works\nEstimated primary completion: 10 October 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cemdisiran#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05744921
URL:https://assetmemo.bio/drug/cemdisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631637-6930@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:ALN-CIDEB: Phase 2 readout est. (NCT07631637)
DESCRIPTION:ALN-CIDEB\, phase 2\, MASH / NASH.\nStudy: Study to Evaluate AL
 N-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohep
 atitis (MASH)\nEstimated primary completion: 29 January 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07631637
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854782-6930@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290303
DTEND;VALUE=DATE:20290304
SUMMARY:ALN-CIDEB: Phase 3 readout est. (NCT07854782)
DESCRIPTION:ALN-CIDEB\, phase 3\, MASH / NASH.\nStudy: Trial to Evaluate AL
 N-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Di
 sease (MASLD)\nEstimated primary completion: 3 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07854782
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05739383-1034@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290416
DTEND;VALUE=DATE:20290417
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05739383)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: A Study of Inclisiran to Prevent Cardiovascular Events in
  High-risk Primary Prevention Patients.\nEstimated primary completion: 16 
 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisira
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 739383
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933328-6930@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290507
DTEND;VALUE=DATE:20290508
SUMMARY:ALN-CIDEB: Phase 2 readout est. (NCT07933328)
DESCRIPTION:ALN-CIDEB\, phase 2.\nStudy: Study to Evaluate ALN-CIDEB in Adu
 lts With Fibrotic Alcohol-Associated Liver Disease (ALD)\nEstimated primar
 y completion: 7 May 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/aln-cideb#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07933328
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285460-10760@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290804
DTEND;VALUE=DATE:20290805
SUMMARY:Qfitlia (Fitusiran): Phase 3 readout est. (NCT07285460)
DESCRIPTION:Qfitlia (Fitusiran)\, phase 3.\nStudy: A Study to Investigate t
 he Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 
 1 to Less Than 12 Years With Hemophilia A or B\nEstimated primary completi
 on: 4 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fi
 tusiran#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07285460
URL:https://assetmemo.bio/drug/fitusiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154745-5168@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300118
DTEND;VALUE=DATE:20300119
SUMMARY:Cemdisiran: Phase 3 readout est. (NCT07154745)
DESCRIPTION:Cemdisiran\, phase 3.\nStudy: A Study to Evaluate How Pozelimab
  + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal 
 Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Effi
 ciently\nEstimated primary completion: 18 January 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cemdisiran#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07154745
URL:https://assetmemo.bio/drug/cemdisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527910-6782@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:ALN-PNP: Phase 2 readout est. (NCT07527910)
DESCRIPTION:ALN-PNP\, phase 2\, MASH / NASH.\nStudy: A Phase 2a Study of AL
 N-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous P
 NPLA3-Related MASLD\nEstimated primary completion: 15 March 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/aln-pnp#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07527910
URL:https://assetmemo.bio/drug/aln-pnp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636811-697@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Mivelsiran: Phase 2 readout est. (NCT07636811)
DESCRIPTION:Mivelsiran\, phase 2\, Alzheimer's Disease.\nStudy: A Study to 
 Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-A
 ssociated Alzheimer's Disease (DS-AD)\nEstimated primary completion: 18 Ma
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/mivelsiran#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076368
 11
URL:https://assetmemo.bio/drug/mivelsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052903-10761@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Nucresiran: Phase 3 readout est. (NCT07052903)
DESCRIPTION:Nucresiran\, phase 3\, Transthyretin Amyloidosis with Cardiomyo
 pathy.\nStudy: TRITON-CM: A Study to Evaluate Nucresiran in Patients With 
 Transthyretin Amyloidosis With Cardiomyopathy\nEstimated primary completio
 n: 28 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nucre
 siran#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07052903
URL:https://assetmemo.bio/drug/nucresiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181109-532@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300923
DTEND;VALUE=DATE:20300924
SUMMARY:Zilebesiran: Phase 3 readout est. (NCT07181109)
DESCRIPTION:Zilebesiran\, phase 3\, Hypertension.\nStudy: Zilebesiran in Pa
 tients With Hypertension Not Adequately Controlled and With Either Establi
 shed Cardiovascular Disease or High Risk for Cardiovascular Disease\nEstim
 ated primary completion: 23 September 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/zilebesiran#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07181109
URL:https://assetmemo.bio/drug/zilebesiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05682378-1034@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20320325
DTEND;VALUE=DATE:20320326
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05682378)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Long-term Safety and Tolerability of Inclisiran in Partic
 ipants With HeFH or HoFH Who Have Completed the Pediatric ORION-16\, ORION
 -13\, ORION-20\, or ORION-19 Studies\nEstimated primary completion: 25 Mar
 ch 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisiran#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05682
 378
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
